Meningococcal disease vaccines are crucial in preventing infections caused by Neisseria meningitidis bacteria, which can lead to severe meningitis and septicemia. There are different types of meningococcal vaccines targeting specific serogroups, including A, B, C, W, and Y. Conjugate vaccines, such as MenACWY and MenACWY-CRM, offer protection against multiple serogroups and are routinely recommended for adolescents and young adults. The MenB vaccine targets serogroup B and is recommended for certain high-risk groups. Vaccination against meningococcal disease is particularly emphasized for individuals living in close quarters, such as college students, military personnel, and those traveling to regions with high incidence. Timely immunization is critical to preventing outbreaks and protecting vulnerable populations. Meningococcal vaccines have significantly reduced the incidence of meningococcal disease, but continued surveillance and vaccination efforts are essential. Public health strategies aim to raise awareness, improve vaccine coverage, and address emerging threats to ensure comprehensive protection against meningococcal infections.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey